PDX

Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual Meeting

Retrieved on: 
星期二, 三月 5, 2024
Therapy, Cancer, Neoplasm, PDX, AACR, ADC

BOSTON, March 05, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that the company will present new preclinical data in four posters at the 2024 American Association for Cancer Research (AACR) Annual Meeting in San Diego, California, held from April 5 to 10, 2024.

Key Points: 
  • "Our preclinical research continues to support the broad potential of PYX-201, our innovative clinical stage ADC targeting EDB+FN, a protein associated with the stroma of solid tumors,” said Lara S. Sullivan, M.D., President and Chief Executive Officer of Pyxis Oncology.
  • “Data from PDX tumor preclinical models has shown potent anti-tumor activity in multiple human cancer indications.
  • Finally, we will present anti-tumor efficacy data supporting the potential for PYX-102 as a therapeutic candidate, and remain open to out-licensing opportunities for future development.”
    Poster titles are now available on the AACR website.
  • Posters will be made available on the Pyxis Oncology website following presentations at the conference.

Merus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expression

Retrieved on: 
星期二, 三月 5, 2024
PDX, NRG1, Cancer, AACR, Lung cancer, Safety, Poster, Pancreatic cancer

The abstract describes Zeno’s activity in preclinical models representing different tumor types expressing high neuregulin 1 (NRG1) levels.

Key Points: 
  • The abstract describes Zeno’s activity in preclinical models representing different tumor types expressing high neuregulin 1 (NRG1) levels.
  • High NRG1 expression is associated with poorer prognosis in certain cancers and resistance to standard therapies.
  • The anti-tumor efficacy of Zeno in vivo against a panel of 28 patient-derived xenograft (PDX) models representing different tumor types was examined.
  • Title: Zenocutuzumab, a HER2xHER3 bispecific antibody, is effective in cancer models with high NRG1 expression.

NextGen Ground Handling Service Announces Expansion to Four Additional Airports

Retrieved on: 
星期二, 二月 27, 2024
BIL, Name, Aircraft, PDX, Transport, Airport, Nextgen, PVD, GHS, ULD, RIC

Combined with its existing operations in Billings, Montana (BIL) and Providence, Rhode Island (PVD), NextGen GHS now offers its ground handling services in six airport locations.

Key Points: 
  • Combined with its existing operations in Billings, Montana (BIL) and Providence, Rhode Island (PVD), NextGen GHS now offers its ground handling services in six airport locations.
  • NextGen GHS specializes in comprehensive, efficient operations that integrate all phases of ground handling.
  • In addition, NextGen GHS offers a Ground Service Equipment (GSE) fueling service that provides fast, efficient and reliable fueling.
  • “We are proud to bring our services to four additional airports, serving some of the most respected names in the Airline industry.”

Madaket Health Appoints Healthcare Leaders Megan Schmidt and Tim Suther to Board of Directors

Retrieved on: 
星期三, 二月 21, 2024
Data Management, Practice Management, Technology, Thought Leadership, General Health, Data Analytics, Public Policy, Government, Other Health, Payments, Other Professional Services, Healthcare Reform, Fintech, Health Technology, Finance, Health Insurance, Consulting, Security, Professional Services, Other Technology, Software, Health, PDX, Madaket, Massachusetts, Coalition, Gamma globulin, Spectrum Health, Sale, JPMorgan Chase, Suther, HealthPartners, Acxiom, Vice, PDM, Committee, Insurance, Management

Madaket Health , the leading platform for provider-payer collaboration and data exchange, today announced that Megan Schmidt and Tim Suther have joined the company’s board of directors.

Key Points: 
  • Madaket Health , the leading platform for provider-payer collaboration and data exchange, today announced that Megan Schmidt and Tim Suther have joined the company’s board of directors.
  • Tim Suther has more than three decades of experience maximizing value through data, analytics, and technology transformation.
  • "As the needs of the industry evolve, Madaket is solving administrative challenges burdening the entire healthcare ecosystem," said Schmidt.
  • Both newly appointed board members bring diverse skills and perspectives that will help Madaket continue to expand its reach and solutions in the healthcare industry.

Be Biopharma to Present at Keystone Symposia on Emerging Cellular Therapies

Retrieved on: 
星期四, 一月 25, 2024
Health, Other Science, Research, Pharmaceutical, Science, Biotechnology, Patient, DSM-IV codes, ASM, ALL, Lysosomal storage disease, BCM, ALP, PDX, Cancer, FIX, A-DNA, Transgene, Cell, Protein, BCMS, B cell, Partial thromboplastin time, Vaccine

Be Biopharma, Inc. (“Be Bio”), a company pioneering the development of engineered B Cell Medicines (BCMs), today announced an oral presentation and poster presentation at the Keystone Symposia on Emerging Cellular Therapies meeting, held from January 22 to 25, 2024 in Santa Fe, New Mexico.

Key Points: 
  • Be Biopharma, Inc. (“Be Bio”), a company pioneering the development of engineered B Cell Medicines (BCMs), today announced an oral presentation and poster presentation at the Keystone Symposia on Emerging Cellular Therapies meeting, held from January 22 to 25, 2024 in Santa Fe, New Mexico.
  • The data being presented support the utility of engineered B cell medicines (BCMs) across a broad range of applications.
  • “Gene and cell therapies have transformative potential to treat previously intractable diseases, but have barriers to adoption such as lack of durability, inability to re-dose, and requirement of preconditioning for engraftment.
  • Our BCM platform has the potential to address these barriers,” said Richard A. Morgan, Ph.D., Chief Scientific Officer, Be Bio.

Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications

Retrieved on: 
星期四, 一月 4, 2024
Menarini, Woman, Breast cancer, Breast, PDX, KAT6A, Doctor of Philosophy, Therapy, Insilico Medicine, Cancer, Mutation, Neoplasm, CDX, Artificial intelligence, Patient, Safety, Medical imaging

Insilico presented data on the novel molecule at the San Antonio Breast Cancer Symposium in early December.

Key Points: 
  • Insilico presented data on the novel molecule at the San Antonio Breast Cancer Symposium in early December.
  • This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
  • Breast cancer is the most commonly diagnosed tumor type and the leading cause of cancer death among women, globally.
  • Overexpression of KAT6A correlates with poor clinical outcomes in patients with ER+/HER2- breast cancer, the most common subtype of breast cancer.

Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications

Retrieved on: 
星期四, 一月 4, 2024
Menarini, Woman, Breast cancer, Breast, PDX, KAT6A, Doctor of Philosophy, Therapy, Insilico Medicine, Cancer, Mutation, Neoplasm, CDX, Artificial intelligence, Patient, Safety, Medical imaging

Insilico presented data on the novel molecule at the San Antonio Breast Cancer Symposium in early December.

Key Points: 
  • Insilico presented data on the novel molecule at the San Antonio Breast Cancer Symposium in early December.
  • This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
  • Breast cancer is the most commonly diagnosed tumor type and the leading cause of cancer death among women, globally.
  • Overexpression of KAT6A correlates with poor clinical outcomes in patients with ER+/HER2- breast cancer, the most common subtype of breast cancer.

Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications

Retrieved on: 
星期四, 一月 4, 2024
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Menarini, Multimedia, Woman, Breast cancer, Breast, PDX, KAT6A, Doctor of Philosophy, Therapy, Insilico Medicine, Cancer, Mutation, CDX, Neoplasm, Patient, Safety, Intelligence, Medical imaging

This is a significant clinical challenge and highlights the urgent need for novel therapies to help overcome treatment resistance.

Key Points: 
  • This is a significant clinical challenge and highlights the urgent need for novel therapies to help overcome treatment resistance.
  • Overexpression of KAT6A correlates with poor clinical outcomes in patients with ER+/HER2- breast cancer, the most common subtype of breast cancer.
  • Insilico presented data on the molecule at the San Antonio Breast Cancer Symposium in early December.
  • Currently, endocrine therapy in combination with CDK4/6 inhibitors is the standard treatment for ER+/HER2- breast cancer patients with advanced or metastatic disease.

ChemPartner Unveils Highly Anticipated Biology Database

Retrieved on: 
星期五, 十二月 22, 2023
Biology, Database, Drug discovery, Collection, Drug development, Data analysis, Research, PDX, Literature, Statistics, Biochemistry, CDX, Gene expression, CNS, Genomics, Gene, Pathology, Syngenic, SOC, Mining, Pharmacology, Medical imaging

SHANGHAI, Dec 23, 2023 - (ACN Newswire) - ChemPartner, a global leader in drug discovery and development services, today announced the launch of its long-awaited Biology Database.

Key Points: 
  • SHANGHAI, Dec 23, 2023 - (ACN Newswire) - ChemPartner, a global leader in drug discovery and development services, today announced the launch of its long-awaited Biology Database.
  • The database includes 800+ tumor models, 30+ cancer types, 20,000 genes, 2,300+ pathways, 1,800 SoC data from literature (500 internal), and 30+ analytic modules.
  • To ensure a smooth and efficient rollout of this substantial volume of data, the database will be introduced in stages.
  • The Biology Database, a flagship online collaborative platform, prominently features the Tumor Model Database.

Nuvectis Pharma, Inc. Announces a Collaboration with Mayo Clinic to Evaluate NXP800 in an Investigator-Sponsored Clinical Trial in Cholangiocarcinoma

Retrieved on: 
星期一, 十二月 18, 2023
Platinum, PDX, Ovarian cancer, Mayo Clinic, Human

Fort Lee, NJ, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced a collaboration with Mayo Clinic to evaluate NXP800 in an Investigator-sponsored clinical trial in cholangiocarcinoma. Mitesh Borad, M.D., an oncologist at Mayo Clinic Comprehensive Cancer Center in Arizona, will serve as the principal investigator for the trial.

Key Points: 
  • Fort Lee, NJ, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced a collaboration with Mayo Clinic to evaluate NXP800 in an Investigator-sponsored clinical trial in cholangiocarcinoma.
  • Mitesh Borad, M.D., an oncologist at Mayo Clinic Comprehensive Cancer Center in Arizona, will serve as the principal investigator for the trial.
  • "We are honored to announce this collaboration with Mayo Clinic," said Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis.
  • "Similar to platinum resistant, ARID1a-mutated ovarian cancer, this clinical development program in cholangiocarcinoma represents another opportunity for NXP800 in a serious condition of unmet medical need and we are very hopeful that the robust activity seen in the cholangiocarcinoma PDX models will be translated into clinical activity in humans."